Cutaneous Melanoma

P2, N=151, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Apr 2031 --> Dec 2030 | Trial primary completion date: Mar 2027 --> Nov 2026

Using A375 and SK-MEL-28 melanoma cells treated with the ferroptosis inducer erastin, we analyzed USP36 expression and evaluated its functional role through both overexpression and knockdown experiments...Collectively, these findings establish USP36 as an oncogene in melanoma that inhibits ferroptosis through stabilization of APEX1. Therefore, targeting the USP36-APEX1 axis may represent a novel therapeutic approach for melanoma treatment.

P=N/A, N=36, Recruiting, University of California, Davis | Withheld --> Recruiting

Unexpectedly, the same volume history also increases IFN-γ response, elevates MHC-I, reduces sialylation, and increases susceptibility to CD8+ T cell killing. These findings indicate that persistent volume history can couple drug tolerance programs to an exploitable increase in immune visibility.

PCDS is a cross-cohort robust tool for predicting melanoma prognosis and immunotherapy benefit, reflecting the degree of immunosuppression in the tumor immune microenvironment and myeloid/macrophage-related immunoregulatory features, and provides a basis for individualized risk stratification and potential drug selection. This study provides an in-depth elucidation of the regulatory mechanisms of PCD in the tumor immune microenvironment and offers an important theoretical foundation for personalized treatment decision-making in melanoma patients.

P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | N=18 --> 8 | Trial completion date: Nov 2025 --> Feb 2027

P1, N=22, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Aug 2026

As a result, CF-nPTs achieved pronounced tumor regression, extended survival, and strong immune activation in both subcutaneous melanoma and lymph-node-metastasis models. Collectively, this study identifies protein-corona resistance as a key determinant of nano-PROTACs performance and establishes CF-nPTs as a promising platform for efficient target protein degradation.

P2, N=20, Active, not recruiting, Melanoma Institute Australia | Trial completion date: Jan 2036 --> Oct 2035

P2, N=40, Withdrawn, Sydney Local Health District | Not yet recruiting --> Withdrawn

This study establishes a pan-skin cancer immune remodelling framework, providing a foundation for biomarker discovery and the development of new immunotherapy strategies.